TY - JOUR
T1 - Dexamethasone versus Surgery for Chronic Subdural Hematoma
AU - Miah, Ishita P.
AU - Holl, Dana C.
AU - Blaauw, Jurre
AU - Lingsma, Hester F.
AU - den Hertog, Heleen M.
AU - Jacobs, Bram
AU - Kruyt, Nyika D.
AU - van der Naalt, Joukje
AU - Polinder, Suzanne
AU - Groen, Rob J.M.
AU - Kho, Kuan H.
AU - van Kooten, Fop
AU - Dirven, Clemens M.F.
AU - Peul, Wilco C.
AU - Jellema, Korné
AU - Dammers, Ruben
AU - van der Gaag, Niels A.
AU - DECSA Collaborators
N1 - Funding Information:
Supported by the Netherlands Organization for Health Research and Development ; Jacobus Foundation, the Hague; and Erasmus Medical Center.
Publisher Copyright:
© 2023 Massachusetts Medical Society.
PY - 2023/6/15
Y1 - 2023/6/15
N2 - Background The role of glucocorticoids without surgical evacuation in the treatment of chronic subdural hematoma is unclear. Methods In this multicenter, open-label, controlled, noninferiority trial, we randomly assigned symptomatic patients with chronic subdural hematoma in a 1:1 ratio to a 19-day tapering course of dexamethasone or to burr-hole drainage. The primary end point was the functional outcome at 3 months after randomization, as assessed by the score on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Noninferiority was defined by a lower limit of the 95% confidence interval of the odds ratio for a better functional outcome with dexamethasone than with surgery of 0.9 or more. Secondary end points included scores on the Markwalder Grading Scale of symptom severity and on the Extended Glasgow Outcome Scale. Results From September 2016 through February 2021, we enrolled 252 patients of a planned sample size of 420; 127 were assigned to the dexamethasone group and 125 to the surgery group. The mean age of the patients was 74 years, and 77% were men. The trial was terminated early by the data and safety monitoring board owing to safety and outcome concerns in the dexamethasone group. The adjusted common odds ratio for a lower (better) score on the modified Rankin scale at 3 months with dexamethasone than with surgery was 0.55 (95% confidence interval, 0.34 to 0.90), which failed to show noninferiority of dexamethasone. The scores on the Markwalder Grading Scale and Extended Glasgow Outcome Scale were generally supportive of the results of the primary analysis. Complications occurred in 59% of the patients in the dexamethasone group and 32% of those in the surgery group, and additional surgery was performed in 55% and 6%, respectively. Conclusions In a trial that involved patients with chronic subdural hematoma and that was stopped early, dexamethasone treatment was not found to be noninferior to burr-hole drainage with respect to functional outcomes and was associated with more complications and a greater likelihood of later surgery.
AB - Background The role of glucocorticoids without surgical evacuation in the treatment of chronic subdural hematoma is unclear. Methods In this multicenter, open-label, controlled, noninferiority trial, we randomly assigned symptomatic patients with chronic subdural hematoma in a 1:1 ratio to a 19-day tapering course of dexamethasone or to burr-hole drainage. The primary end point was the functional outcome at 3 months after randomization, as assessed by the score on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]). Noninferiority was defined by a lower limit of the 95% confidence interval of the odds ratio for a better functional outcome with dexamethasone than with surgery of 0.9 or more. Secondary end points included scores on the Markwalder Grading Scale of symptom severity and on the Extended Glasgow Outcome Scale. Results From September 2016 through February 2021, we enrolled 252 patients of a planned sample size of 420; 127 were assigned to the dexamethasone group and 125 to the surgery group. The mean age of the patients was 74 years, and 77% were men. The trial was terminated early by the data and safety monitoring board owing to safety and outcome concerns in the dexamethasone group. The adjusted common odds ratio for a lower (better) score on the modified Rankin scale at 3 months with dexamethasone than with surgery was 0.55 (95% confidence interval, 0.34 to 0.90), which failed to show noninferiority of dexamethasone. The scores on the Markwalder Grading Scale and Extended Glasgow Outcome Scale were generally supportive of the results of the primary analysis. Complications occurred in 59% of the patients in the dexamethasone group and 32% of those in the surgery group, and additional surgery was performed in 55% and 6%, respectively. Conclusions In a trial that involved patients with chronic subdural hematoma and that was stopped early, dexamethasone treatment was not found to be noninferior to burr-hole drainage with respect to functional outcomes and was associated with more complications and a greater likelihood of later surgery.
KW - Emergency medicine
KW - Emergency medicine general
KW - Geriatrics/aging
KW - Geriatrics/aging general
KW - Head trauma
KW - Neurology/neurosurgery
KW - Neurology/neurosurgery general
KW - Surgery
KW - Surgery general
KW - Trauma
KW - n/a OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85163905040&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa2216767
DO - 10.1056/NEJMoa2216767
M3 - Article
C2 - 37314705
AN - SCOPUS:85163905040
SN - 0028-4793
VL - 388
SP - 2230
EP - 2240
JO - New England journal of medicine
JF - New England journal of medicine
IS - 24
ER -